17
Sep
2026

Scholar Rock Gets FDA OK, Reverse Mergers Continue & Novartis Bets on Brain Delivery

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

RevMed’s Rollout, Yosemite Invests in Cancer & Servier’s Phase III Whiff
Anthropic Makes Noise, Silence Gets Bought, & GSK Gets HepB OK
BMS Hits IPF Goal, Iambic and City IPO & AZ Invests in Insitro
Merck Bets on KRAS Drug, Kodiak Hunts Down Regeneron, & Lycia Preps for IPO